A detailed history of Squarepoint Ops LLC transactions in Pro Qr Therapeutics N.V. stock. As of the latest transaction made, Squarepoint Ops LLC holds 71,491 shares of PRQR stock, worth $157,280. This represents 0.0% of its overall portfolio holdings.

Number of Shares
71,491
Previous 84,733 15.63%
Holding current value
$157,280
Previous $140,000 7.14%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.64 - $2.24 $21,716 - $29,662
-13,242 Reduced 15.63%
71,491 $130,000
Q2 2024

Aug 14, 2024

SELL
$1.65 - $2.39 $111,818 - $161,967
-67,769 Reduced 44.44%
84,733 $140,000
Q1 2024

May 15, 2024

BUY
$1.89 - $2.85 $45,979 - $69,334
24,328 Added 18.98%
152,502 $349,000
Q4 2023

Feb 14, 2024

SELL
$1.15 - $2.21 $6,863 - $13,189
-5,968 Reduced 4.45%
128,174 $253,000
Q2 2023

Aug 14, 2023

BUY
$1.62 - $2.32 $217,310 - $311,209
134,142 New
134,142 $217,000
Q2 2022

Aug 15, 2022

SELL
$0.56 - $1.0 $27,931 - $49,878
-49,878 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$0.9 - $8.39 $44,890 - $418,476
49,878 New
49,878 $45,000
Q4 2021

Feb 14, 2022

SELL
$6.58 - $8.44 $118,762 - $152,333
-18,049 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$5.16 - $8.47 $93,132 - $152,875
18,049 New
18,049 $151,000
Q2 2021

Aug 16, 2021

SELL
$5.75 - $7.59 $432,377 - $570,737
-75,196 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$4.14 - $9.22 $229,318 - $510,705
55,391 Added 279.68%
75,196 $497,000
Q4 2020

Feb 16, 2021

BUY
$3.58 - $4.85 $70,901 - $96,054
19,805 New
19,805 $83,000
Q1 2019

May 15, 2019

SELL
$12.5 - $18.48 $133,750 - $197,736
-10,700 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$15.25 - $22.4 $163,175 - $239,679
10,700 New
10,700 $169,000

Others Institutions Holding PRQR

About ProQR Therapeutics N.V.


  • Ticker PRQR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,362,096
  • Market Cap $157M
  • Description
  • ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...
More about PRQR
Track This Portfolio

Track Squarepoint Ops LLC Portfolio

Follow Squarepoint Ops LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.